Thomas Ingolia has become the new CEO of Myriad Proteomics, based in Salt Lake City, replacing acting CEO Peter Meldrum. He started his new appointment this week. Most recently, Ingolia was working as a consultant for biopharma. Prior to that, he was president of Microbia of Cambridge, Mass. Before that, he held positions at Ontogeny, based in Cambridge, which subsequently became Curis. He also served in various positions at Eli Lilly. Ingolia holds a PhD in biochemistry from the University of California, Berkeley and an MBA from Indiana University.
Alex Mackenzie has become vice president of research for Genome Canada, effective July 1. He is currently director at the Children’s Hospital of Eastern Ontario’s Research Institute in Ottawa and professor of the faculty of medicine at the University of Ottawa.